FDA Approves Welireg With Lenvatinib for Advanced Kidney Cancer

Quick answer: On 24 September 2026, the US FDA approved Welireg (belzutifan, Merck) to be taken together with lenvatinib (Lenvima, Eisai) for adults with advanced clear cell kidney cancer that has already been treated with PD-1 or PD-L1 immunotherapy. In the LITESPARK-011 trial, the pair held the cancer back for a median of 14.6 months, compared with 10.6 months on cabozantinib.

If you're caring for someone with kidney cancer that kept growing after immunotherapy, you already know the hardest question in that clinic room: what do we try next? This approval gives doctors one more answer at exactly that point. We read the FDA's announcement line by line, and below is what it actually says, in plain words, with nothing added.

So, What Did the FDA Actually Approve?

Welireg itself isn't new. What's new is pairing it with lenvatinib for adults whose clear cell kidney cancer (ccRCC) has:

• kept growing on or after a PD-1 or PD-L1 immunotherapy, or
• come back within six months of finishing PD-1 treatment given after surgery (what doctors call adjuvant therapy)

The dose is straightforward: 120 mg of belzutifan and 20 mg of lenvatinib, once a day, for as long as the treatment keeps working and the side effects stay manageable.

How Well Did It Work? The LITESPARK-011 Numbers

The FDA based its decision on one trial, LITESPARK-011, which enrolled 747 people with advanced ccRCC. Half were given belzutifan plus lenvatinib. The other half got cabozantinib, another oral kidney cancer drug. Here's how the two groups compared.

Time before the cancer grew again

Doctors call this progression-free survival, and it's where the combination clearly came out ahead.

• Belzutifan + lenvatinib: 14.6 months (median)
• Cabozantinib: 10.6 months (median)
• Hazard ratio 0.74, a statistically significant difference

Put simply, the middle patient on the combination went four months longer before their disease moved again.

How many tumours shrank

53% of people on the combination saw their tumours shrink. On cabozantinib, it was 40%.

The part that's easy to miss: overall survival

People on the combination lived a median of 33.7 months, against 28.6 months on cabozantinib. On paper that looks like a clear win, but the FDA is careful to point out that in the final analysis this difference was not statistically significant. We'd rather say that plainly than bury it: the proven benefit is more time before the cancer grows, not a proven longer life.

Side Effects Worth Asking About

No treatment for advanced kidney cancer is gentle, and this pair comes with its own list. From the FDA notice:

• Pregnancy: Welireg carries a boxed warning, the FDA's most serious kind, for harm to an unborn baby.
• Blood and breathing: Welireg can cause anaemia and low oxygen levels (hypoxia).
• Heart: taken together, the two drugs also carry a warning for heart problems (cardiac dysfunction).
• Lenvatinib's own list: high blood pressure, liver and kidney problems, protein in the urine, diarrhoea and bleeding, among others.

Questions Worth Taking to Your Oncologist

You don't need to become an expert overnight. A few good questions go a long way:

• Did my cancer grow on PD-1 or PD-L1 immunotherapy, or come back within six months of adjuvant PD-1 treatment?
• How does this combination compare with cabozantinib for someone in my situation?
• Given the warnings about anaemia, low oxygen and the heart, what tests will I need, and how often?
• If pregnancy is possible, what precautions should we take?

What It Means If You're in India

This approval adds to the uses Welireg already had: von Hippel-Lindau disease, advanced ccRCC after earlier treatment and, since June 2026, adjuvant therapy with pembrolizumab. We've covered those in our guide to Welireg for kidney cancer.

If your oncologist feels this combination suits your case, our Welireg page explains how a doctor can request it through a Named Patient Program. And if the paperwork feels overwhelming (for most families it does), talk to our team and we'll walk you through it.

We write these updates to help patients and families keep up with changes that matter. They aren't medical advice, and every treatment decision belongs with your oncologist.

Last reviewed: 29 September 2026, against the FDA announcement listed below.

References

1. US FDA: FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component (24 Sep 2026)
2. ClinicalTrials.gov: LITESPARK-011, belzutifan plus lenvatinib versus cabozantinib in renal cell carcinoma (NCT04586231)